Every 8-K that Cibus, Inc. (CBUS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CBUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBUS filings page.
Cibus, Inc. reported second quarter 2026 results and a business update centered on commercial execution in Rice herbicide-tolerance traits and its Sustainable Ingredients program. The company expanded its relationship with Rice customer Interoc from two to five traits and now has seven Rice seed-company customers across Latin America and the United States, targeting initial Latin American launches around 2028 and a U.S. launch aligned with a 2029 herbicide-registration timeline.
Cibus highlighted favorable regulatory developments, including U.S. treatment of its traits as conventional breeding, completion of an FDA review of an altered-lignin Alfalfa trait, and new European Union legislation generally treating precisely edited, non-transgenic crops as conventionally bred. Cash and cash equivalents were $20.4 million as of June 30, 2026; the company expects this to fund operations into early in the first quarter of 2027. Quarterly net cash usage declined, and management now targets an annual net cash usage run-rate of about $35 million exiting 2026. Revenue was $0.994 million, R&D expense fell to $8.5 million, SG&A to $5.4 million, and net loss narrowed to $22.1 million, compared with $26.6 million a year earlier.
Cibus, Inc. appointed Craig Wichner as Chief Executive Officer as part of its succession plan, effective June 8, 2026. Wichner, formerly a director, brings experience as founder and managing partner of Farmland LP, a U.S. farmland investment firm with more than $350 million in assets and over 19,000 acres under management.
Interim CEO Peter Beetham returned to his prior role as President and Chief Operating Officer, and both he and Wichner resigned from the Board, reducing the Board size to seven directors. Wichner’s employment agreement sets an initial base salary of $650,000, bonus eligibility, severance protections, and change-in-control benefits.
On June 8, 2026, Wichner received a restricted stock unit award valued at $1.1 million and a stock option award also valued at $1.1 million, each vesting in four equal annual installments. The company highlighted its focus on executing near-term commercialization targets and capital strategy under the new leadership.
Cibus, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Of 76,345,736 shares of Class A common stock entitled to vote as of the April 6, 2026 record date, 53,072,072 shares, or about 69.52%, were represented, establishing a quorum.
Stockholders elected nine directors, including Mark Finn and Peter Beetham, to one-year terms. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Cibus, Inc. reported first quarter 2026 results showing higher revenue and a significantly smaller loss while advancing key agricultural trait programs. Revenue for the quarter ended March 31, 2026 was $1.7 million, up from $1.0 million a year earlier, reflecting progress across programs.
Research and development expense fell to $8.7 million and SG&A to $5.1 million, helped by cost reduction initiatives and the absence of a $21.0 million goodwill impairment recorded in the prior-year quarter. Net loss narrowed to $21.2 million from $49.4 million, and net loss per share improved to $0.33 from $1.34.
Cash and cash equivalents rose to $30.3 million as of March 31, 2026, supported by two equity offerings raising $22.3 million and approximately $15.0 million in gross proceeds. The company expects existing cash to fund planned operations into late in the first quarter of 2027 while it moves its Rice herbicide tolerance and Sustainable Ingredients programs toward commercialization.
Cibus, Inc. reported that its Board of Directors appointed Thomas Urban as a director, effective April 7, 2026. Urban is the founder of Agribusiness Advisors and has held leadership roles at CellFor, ArborGen, and Pioneer Hi-Bred International, and began his career at Goldman Sachs.
He will enter into the company’s standard indemnification agreement for directors and, under the Non-Employee Director Compensation Policy, will receive a $60,000 annual cash retainer and equity awards with a grant date value of $90,000, both prorated through the next annual shareholder meeting.
Cibus, Inc. entered an underwriting agreement with BTIG, LLC for an underwritten public offering of 6,976,744 shares of Class A common stock at $2.15 per share. The company expects net proceeds of about $13.5 million, or $16.0 million if the 1,046,511-share overallotment option is fully exercised.
The offering is expected to close on or about March 27, 2026, subject to customary conditions, under a previously effective Form S-3 shelf registration. The underwriter will receive a 7.0% discount on gross proceeds, and directors, officers and the company agreed to a 60-day lock-up on additional sales, with customary exceptions.
Cibus, Inc. reported continued heavy losses alongside commercial and regulatory progress. For the quarter ended December 31, 2025, revenue was $1.1 million while net loss widened to $31.9 million, reflecting $9.1 million of long‑lived asset impairment tied to winding down its Roseville, Minnesota facility.
Full‑year 2025 revenue was $3.6 million and net loss was $132.2 million, a substantial but still large loss compared with 2024, which included a major goodwill impairment. Cost‑saving initiatives reduced research and development and selling, general and administrative expenses year over year.
Cash and cash equivalents were $9.9 million at December 31, 2025. Including $19.8 million in net proceeds from a January 2026 public offering and expected savings, Cibus believes it can fund operations into late in the third quarter of 2026. The board and its financial advisor are evaluating strategic alternatives while the company advances its rice herbicide tolerance program, sustainable ingredients initiative, and broader gene‑editing trait pipeline.
Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for a public offering of 13,333,333 shares of Class A common stock at $1.50 per share. The company expects net proceeds of about $17.8 million, or $20.5 million if BTIG exercises its 30-day option to buy up to 1,999,999 additional shares.
Members of the board of directors will purchase 1,000,000 shares at the offering price, and directors, executive officers and the company agreed to a 60-day lock-up on additional sales, subject to limited exceptions. BTIG will receive a 6.25% underwriting discount and reimbursement of documented expenses up to $150,000. The deal is expected to close on or about January 30, 2026, subject to customary conditions.
Cibus, Inc. filed an update describing its business focus and cost-cutting steps made alongside an underwritten offering. The agricultural biotechnology company develops gene-edited plant traits it licenses to seed companies for per‑acre royalties, targeting productivity, sustainability, and yield improvements.
The company is prioritizing herbicide-tolerant weed management traits for Rice, estimating potential annual accessible royalties of over $200 million in Latin America and the United States, and additional royalty opportunities in Asia and India. Management’s longer-term goal is to address about 200 million of the roughly 400 million global rice acres.
Cibus is also advancing sustainable ingredients programs, including a yeast fermentation biofragrance line that management believes could generate $20–40 million in annual revenue over time. Through 2025 it streamlined operations, including a workforce reduction completed by December 31, 2025, and expects these actions to reduce annual net cash usage to about $30 million or less during 2026 while it consolidates core operations in San Diego and concentrates spending on Rice programs.
Cibus, Inc. reported its results for the three months ended September 30, 2025 and provided a year‑to‑date business update. The company furnished a press release with details as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, limiting its use for liability purposes unless specifically incorporated by reference. The report was signed by Interim Chief Executive Officer Peter Beetham on November 13, 2025.
Cibus, Inc. (CBUS) appointed Craig Wichner to its Board of Directors, effective November 5, 2025, and named him to the Board’s Strategy Committee.
Wichner is the Founder and Managing Partner of Farmland LP, a U.S. farmland investment manager with more than $350 million in assets and over 19,000 acres under management. His annual director compensation includes a $60,000 cash retainer (payable semi-annually) and equity with a grant date value of $90,000, prorated for the remainder of fiscal 2025, subject to Board approval under the company’s 2017 Omnibus Incentive Plan. He also entered into the company’s standard indemnification agreement.
Cibus, Inc. disclosed an Executive Employment Agreement appointing Cornelis (Carlo) Broos as Chief Financial Officer effective September 18, 2025 (agreement dated September 19, 2025). The agreement is at-will but provides severance protections: 18 months of continued base salary if the company terminates him without Cause or he leaves for Good Reason; and enhanced 24-month severance plus a lump-sum bonus equal to his target annual bonus (or a projected portion if termination occurs in the second half of the fiscal year) and full vesting of unvested equity if termination happens in connection with a Change in Control. Severance payments require customary release delivery. For tax efficiency, about half of Mr. Broos’ compensation will be paid to a Belgian entity wholly owned by him. The filing notes no family relationships or other arrangements related to the appointment.
Cibus, Inc. notified the appointment and compensation terms for non-employee director Ms. Box. The Board adopted a Non-Employee Director Compensation Policy providing Ms. Box an annual cash retainer of $60,000 payable semi-annually and equity compensation with a grant-date value of $90,000 to be issued under the Cibus, Inc. 2017 Omnibus Incentive Plan, as amended. The award will be prorated to reflect Ms. Box's service for the remainder of the 2025 fiscal year. The filing is signed by Peter Beetham, Ph.D., Interim Chief Executive Officer.
Cibus, Inc. submitted a current report describing that it has announced its financial results for the three months ended June 30, 2025 and provided a year-to-date business update. These results and the business update are contained in a press release dated August 14, 2025, which is furnished as Exhibit 99.1.
The company clarifies that this press release is being furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Cibus by Interim Chief Executive Officer Peter Beetham.